Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …

abstract Biologics have been a key component of severe asthma treatment, and there are
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …

Background Severe asthma is a major cause of morbidity. Some patients may benefit from
biological therapies. Most evaluations of these treatments are derived from randomized …

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) affects around 60% of
patients with severe eosinophilic asthma (SEA). Benralizumab was recently approved for …

Background Benralizumab can be utilized as add-on biological treatment of severe
eosinophilic asthma. However, so far only a few real-life studies have been published with …

Abstract Background The ORBE II study aimed to describe the characteristics and clinical
outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab …

Advances in pathophysiological understanding and the elucidation of a type 2 inflammatory
signature with interleukins 4, 5 and 13 at its center have led to the development of targeted …

Background Data from phase 3 trials have demonstrated the efficacy and safety of
benralizumab in patients with severe eosinophilic asthma (SEA). We conducted a real-world …

Background Real-world evidence characterizing the clinical outcomes and economic impact
on patients with severe eosinophilic asthma treated with benralizumab is limited. Objective …

Background Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5)
receptor (IL-5R), was used before marketing authorisation in Spain in a real world setting as …